HCV Policy & Advocacy
Cost of Comprehensive Global Hepatitis Prevention and Treatment Might Peak at $11 Billion in 2025
- Details
- Category: HCV Policy & Advocacy
- Published on Friday, 25 September 2015 00:00
- Written by Keith Alcorn
Reaching the World Health Organization’s (WHO) proposed targets for viral hepatitis control by 2030 could require global funding of US$11 billion per year by 2025, Stefan Wiktor of the WHO Hepatitis Program told the World Hepatitis Summit in Glasgow earlier this month.
Medicines Patent Pool Looks at Hepatitis C
- Details
- Category: HCV Policy & Advocacy
- Published on Tuesday, 15 September 2015 00:00
- Written by Keith Alcorn
Greg Perry, Executive Director of the Medicines Patent Pool, told delegates at the recent World Hepatitis Summit in Glasgow that the organization was considering how it could act to speed up and expand access to HCV direct-acting antivirals for lower- and middle-income countries, where around 85% of people with hepatitis C are estimated to live.
Hepatitis C Treatment Guidelines Add Section on Cost-Effectiveness
- Details
- Category: HCV Policy & Advocacy
- Published on Wednesday, 02 September 2015 00:00
- Written by AASLD/IDSA
HCVguidelines.org, a regularly updated website providing U.S. guidelines for testing, managing, and treating people with hepatitis C, has revised several sections and added a new section looking at the cost-effectiveness of treatment using new interferon-free direct-acting antiviral regimens.
World Health Organization Calls for Ambitious Global Targets for Viral Hepatitis Control
- Details
- Category: HCV Policy & Advocacy
- Published on Tuesday, 08 September 2015 00:00
- Written by Keith Alcorn
The World Health Organization (WHO) is calling for ambitious new global targets for diagnosis, treatment, and cure of hepatitis B and C, signaling a major increase in momentum towards elimination of viral hepatitis by 2030, participants heard at the World Hepatitis Summit last week in Glasgow.
EASL 2015: Survey Shows Half of People with Hepatitis B or C Experience Discrimination
- Details
- Category: HCV Policy & Advocacy
- Published on Wednesday, 27 May 2015 00:00
- Written by EASL
A majority of people with hepatitis B or C tell family, friends, and sometimes work colleagues about their infection, but this often leads to discrimination including avoiding physical contact, not being invited to social events, and even loss of employment, according to study of American and European patients presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.
More Articles...
- DDW 2015: Hepatitis C Treatment Could Yield Large Economic Benefit
- EASL 2015: Hepatitis C Treatment May Be Highly Cost-effective for Prisoners in England
- Obama Budget Boosts U.S. HIV and Hepatitis Funding, Cuts Global AIDS and TB
- 3. High Hepatitis C Treatment Cost Leads to Restrictions, Sets Off Price War
Web Design and Development by